We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
- Authors
Maynard, Sharon E; Min, Jiang-Yong; Merchan, Jaime; Lim, Kee-Hak; Li, Jianyi; Mondal, Susanta; Libermann, Towia A; Morgan, James P; Sellke, Frank W; Stillman, Isaac E; Epstein, Franklin H; Sukhatme, Vikas P; Karumanchi, S Ananth
- Abstract
Preeclampsia, a syndrome affecting 5% of pregnancies, causes substantial maternal and fetal morbidity and mortality. The pathophysiology of preeclampsia remains largely unknown. It has been hypothesized that placental ischemia is an early event, leading to placental production of a soluble factor or factors that cause maternal endothelial dysfunction, resulting in the clinical findings of hypertension, proteinuria, and edema. Here, we confirm that placental soluble fms-like tyrosine kinase 1 (sFlt1), an antagonist of VEGF and placental growth factor (PlGF), is upregulated in preeclampsia, leading to increased systemic levels of sFlt1 that fall after delivery. We demonstrate that increased circulating sFlt1 in patients with preeclampsia is associated with decreased circulating levels of free VEGF and PlGF, resulting in endothelial dysfunction in vitro that can be rescued by exogenous VEGF and PlGF. Additionally, VEGF and PlGF cause microvascular relaxation of rat renal arterioles in vitro that is blocked by sFlt1. Finally, administration of sFlt1 to pregnant rats induces hypertension, proteinuria, and glomerular endotheliosis, the classic lesion of preeclampsia. These observations suggest that excess circulating sFlt1 contributes to the pathogenesis of preeclampsia.
- Publication
The Journal of clinical investigation, 2003, Vol 111, Issue 5, p649
- ISSN
0021-9738
- Publication type
Journal Article
- DOI
10.1172/JCI17189